Background: Ovarian adenosquamous carcinoma is an extremely rare type of ovarian histology. Platinum-refractory disease is also uncommon, but can be fatal because of the lack of available treatment options. To date, there is no study or case report on platinum-refractory ovarian adenosquamous carcinoma or its relevant treatment.
Case presentation: Herein, we report the case of a 38-year-old Chinese woman with platinum-refractory advanced ovarian adeno squamous carcinoma who received clinical benefit from poly adenosine diphosphate ([ADP] ribose) polymerase and programmed death-1 inhibitors after failure of prior multiline chemotherapies and antiangiogenic agents. The targeted therapy and immunotherapy-controlled disease deterioration and improved performance status. Thus far, the patient has survived longer than 15 months, and she is taking nivolumab as maintenance treatment.
Conclusion: Targeted therapy and immunotherapy may be options for rare categories of ovarian cancer, but this warrants more clinical evidence of efficacy and toxicity.
[1]Shanghai Univ Tradit Chinese Med, Shanghai 201203, Peoples R China.
[2]Second Mil Med Univ, Changhai Hosp, Dept Gynecol Tradit Chinese Med, 168 Changhai Rd, Shanghai 200433, Peoples R China.
[3]Second Mil Med Univ, Changhai Hosp, Dept Radiol, Shanghai 200433, Peoples R China.
[4]Second Mil Med Univ, Dept Biochem & Mol Biol, Shanghai 200433, Peoples R China.
[5]Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Assisted Reprod, Sch Med, Shanghai 200011, Peoples R China.
(8.0+极速模式)